Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL707611 | 0.78 | — | — | |
| SCHEMBL28411403 | 0.75 | KCNJ1 (0.34) | KCNJ1POLBBLMTDP1MAPT | |
| SCHEMBL5278040 | 0.72 | KCNJ1 (0.36) | KCNJ1POLBBLMTDP1MAPT | |
| SCHEMBL14678292 | 0.71 | — | — | |
| SCHEMBL4502875 | 0.70 | — | — | |
| SCHEMBL8540480 | 0.69 | — | — | |
| SCHEMBL14321614 | 0.69 | — | — | |
| SCHEMBL29110810 | 0.68 | — | — | |
| SCHEMBL8401872 | 0.67 | KCNJ1 (0.41) | KCNJ1 | |
| SCHEMBL8399476 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170849-B1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LTD (GB) | 2016-12-21 | — | — | EP | disclosed |
| US-9187465-B2 | Oxazole tyrosine kinase inhibitors | SAREUM LIMITED (GB) | 2015-11-17 | — | — | US | disclosed |
| US-20150057282-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| US-8921544-B2 | Oxazole tyrosine kinase inhibitors | SAREUM LIMITED (GB) | 2014-12-30 | — | — | US | disclosed |
| US-20140275041-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
| US-20130102592-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2013-04-25 | — | — | US | disclosed |
| US-8378095-B2 | Oxazole tyrosine kinase inhibitors | Saruem Limited (GB) | 2013-02-19 | — | — | US | disclosed |
| US-20100298301-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| WO-2010055304-A2 | PHARMACEUTICAL COMPOUNDS | SAREUM LIMITED (GB) | 2010-05-20 | — | — | WO | disclosed |
| EP-2170849-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | Sareum Limited (GB) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008139161-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275041-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | FLT3, AURKA, FLT1 | KCNJ1 1242/4885POLB 2590/4885BLM 3515/4885 |
| US-20100298301-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | FLT3, AURKA, FLT1 | KCNJ1 1242/4885POLB 2590/4885BLM 3515/4885 |
| US-20150057282-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | FLT3, AURKA, FLT1 | KCNJ1 1242/4885POLB 2590/4885BLM 3515/4885 |
| US-20130102592-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | FLT3, AURKA, FLT1 | KCNJ1 1510/4885POLB 2614/4885BLM 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.